Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials
Introduction
Thalassemia and hemoglobin disorders are an emerging global health burden, [1] accounting for about 3.4% of deaths in children less than 5 years of age [2]. The current therapeutic management of thalassemia is based on regular blood transfusions and iron chelation therapy [3]. Chelation aims to reduce iron stores or correct iron imbalance, and constitutes a major improvement for all people with thalassemia major [3]. Therefore, standards for the treatment of children and adults with thalassemia have been developed [4], [5].
The three main chelators used in current clinical practice are deferoxamine (DFO) (Desferal®; Novartis), deferiprone (DFP) (Ferriprox®; Apotex), and deferasirox (DFX) (Exjade®; Novartis) [6]. The main findings concerning the effectiveness and safety profiles of DFO, DFP, and DFX have been described extensively elsewhere [7], [8], [9], [10], [11]. Moreover, there is also growing off-license usage of DFP in associated with (administration of the two drugs during the same day) or in sequential with (administration of the two drugs on different days) DFO following recent reports of their synergistic effect, particularly with regard to the iron burden in the heart [12], [13]. We identified eight published reviews on iron chelators with our search strategy [14], [15], [16], [17], [18], [19], [20], [21]. However, only four of these included meta-analyses, [19] none included sequential chelation treatment, and none reported GRADE. Moreover, none was conducted systematically, i.e. based on a previously public protocol guiding the review process. Furthermore, none assessed the risks of systematic errors (‘bias’), random errors (‘play of chance’), and design errors [22], [23], [24].
Because these questions remain unanswered, the main objective of our study was to conduct a systematic review of the clinical effectiveness profile of iron chelators for patients with transfusion-dependent thalassemia major, according to previously published criteria[25].
Section snippets
Literature searches
The following electronic databases were utilized (AG and FA) to search for relevant published literature: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ISI Web of Knowledge, the ClinicalTrials.gov register, Current Controlled Trials, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and the reference lists of articles. The date of the last search was June 2010. Two authors (AG and FA) independently scanned all titles and abstracts
Search results
The results of our research strategies are summarized in Fig. 1. Sixteen RCTs were included in this review with a total of 1520 patients aged from 5 to 50 years. Five RCTs were long-term follow-ups of the trials already included in the analysis. Within these 16 trials, 11 different comparisons were detected. In these, the chelators were compared with each other as monotherapies, in combination with each other, or as sequentially administered chelators. Table 2 reports the main findings of the
Discussion
The aim of this systematic review was to evaluate the effectiveness of DFO, DFP, and DFX alone or in associated or as sequential therapies in transfusion-dependent patients with thalassemia major. This meta-analysis suggests that ejection fraction at the end of the intervention was statistically significantly higher after combined (Fig. 4a) or sequential DFP and DFO treatments (Fig. 4b). Liver iron concentration at the end of the intervention was statistically significantly decreased after
Support and sponsorships
Nine trials reported the source of funding [11], [13], [29], [31], [41], [44], [45], [46], [47].
The trials that received funding from a governmental agency included co-funding from the Sicilian Thalassaemic Association and European Community [47].
The trials that documented support from industry included Novartis Pharma [11] and Lipomed, Switzerland, for DFP, [29], [44] and Novartis Pharmaceuticals Corporation, [46] Apotex, Novartis, Apopharma [45].
One trial received funding from both non
Authorship contributions
AF, AV, GA, AM, and CG designed the research, performed the research, and prepared an initial draft of the paper.
AK, AC, MDC, SF, PC, RWG, LP, JBP, FB, and FC analyzed the data and discussed the draft issue by issue.
AF and AM wrote the final draft of the paper.
PH and JW addressed scientific and language issues as international external reviewers.
AI was a representative of the patients who examined the document.
Declarations of interest
Conflict of interest disclosure: AF, AM, AV, GA, CG, FB, LP, FC, AI, RWG, AC, and SF declare no competing financial interests; MDC, PC, and JBP report having received consulting fees from Novartis Pharmaceuticals. PH received research grants from Novartis, and support from Novartis and Ferrokin, and participated in medical advisory boards for Apotex; JW received research grants from Novartis and is a consultant for Ferrokin Biosciences. AK reports participating in study monitor committees for
Acknowledgments
The research leading to these results has received funding by the Italian Ministry of Health and the Italian Foundation for the Cure of Thalassaemia “Leonardo Giambrone”, under the project “Inter-regional Network for Thalassaemia: HTA for the diagnostic and therapeutic intervention for iron overload”, coordinated by the Basilicata Region. Prof. David Nathan provided valuable advice that was greatly appreciated. We thank Foundation Franco and Piera Cutino for their continuous encouragement.
References (50)
The inherited diseases of hemoglobin are an emerging global health burden
Blood
(2010)- et al.
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses
Lancet
(1998) - et al.
Systematic review and meta-analysis methodology
Blood
(2010) - et al.
A phase 3 study of deferasirox (ICL670), a once-daily iron chelator; in patients with beta-thalassemia
Blood
(2006) - et al.
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
Blood
(2006) - et al.
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial Under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
Blood Cells Mol. Dis.
(2009) - et al.
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance
J. Cardiovasc. Magn. Reson.
(2008) - et al.
Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
J. Lab. Clin. Med.
(2001) - et al.
Chelation therapy in beta-thalassemia: an optimistic update
Semin. Hematol.
(2001) - et al.
Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis
Blood
(2006)
Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major
Blood
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
Lancet
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial
Blood Cells Mol. Dis.
Global epidemiology of haemoglobin disorders and derived service indicators
Bull. World Health Organ.
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
Haematologica
Transfusion and iron chelation
Light and shadows in the iron chelation treatment of haematological diseases
Br. J. Haematol.
Desferal — Summary of Product Characteristics
Ferriprox EPAR
British National Formulary (BNF). No. 53, March 2007
Ferriprox: Annex I — Summary of Product Characteristics
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
Haematologica
Combined therapy with deferiprone and desferrioxamine in thalassemia major
Haematological
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
Circulation
Cited by (57)
β-Thalassemia heterozygote state detrimentally affects health expectation
2018, European Journal of Internal MedicineCitation Excerpt :Indeed, just the cost of admission for cirrhosis in these patients could potentially justify intervention to prevent morbidity and to minimise the human and economical burdens [40]. The possibility of preventing today iron body burden complications by use of oral chelation could make prevention of some of these complications possible [41]. The major limitations of the present study are that these findings have been collected retrospectively, although in the largest cohort of individuals to date.
Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies
2024, International Journal of Molecular SciencesIron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications
2023, International Journal of Molecular SciencesDeferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects
2023, International Journal of Molecular SciencesCrosstalk of ferroptosis and oxidative stress in infectious diseases
2023, Frontiers in Molecular BiosciencesEffects of deferoxamine versus deferasirox on hematology and liver parameters in children with beta-thalassemia major: A cross-sectional study from a single center
2023, Iranian Journal of Pediatric Hematology and Oncology